CBX7 and bacterial infectious disease: Furthermore, Iqbal et al. [50] have reported that CBX2 and CBX7 could predict the outcomes and sensitivity to FDA-approved/investigational drugs in BRCA, and pathways related to NFKBIE could lead to the activation of NF-KappaB by PKR and bacterial infections in CF airways.